{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:38:23Z","timestamp":1792024703353,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the Netherlands (NL) the government assigned 2 hospitals as centres of expertise (CE) for Phenylketonuria (PKU), while in the United Kingdom (UK) and Germany no centres are assigned specifically as PKU CE\u2019s.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>To identify expectations of patients\/caregivers with PKU of CEs, a web-based survey was distributed through the national Phenylketonuria societies of Germany, NL and UK.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 105 responded (43 patients, 56 parents, 4 grandparents, 2 other) of whom 59 were from NL, 33 from UK and 13 from Germany. All participants (n\u2009=\u2009105) agreed that patients and\/or practitioners would benefit from CEs. The frequency patients would want to visit a CE, when not treated in a CE (n\u2009=\u200983) varied: every hospital visit (24%, n\u2009=\u200920), annual or bi-annual (45%, n\u2009=\u200937), at defined patient ages (6%, n\u2009=\u20095), one visit only (22%, n\u2009=\u200918), or never (4%, n\u2009=\u20093). Distance was reported as a major barrier (42%, n\u2009=\u200935). 78% (n\u2009=\u200965) expected CE physicians and dieticians to have a higher level of knowledge than in non-CE centres. For participants already treated in a CE (n\u2009=\u200968), 66% requested a more extensive annual or bi-annual review. In general, psychology review and neuropsychologist assessment were identified as necessary by approximately half of the 105 participants. In addition, 66% (n\u2009=\u200968) expected a strong collaboration with patient associations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In this small study, most participants expected that assigning CEs will change the structure of and delivery of Phenylketonuria care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-020-01647-7","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T18:03:54Z","timestamp":1609956234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patient\u2019s thoughts and expectations about centres of expertise for PKU"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9402-4833","authenticated-orcid":false,"given":"A. M. J.","family":"van Wegberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Abeln","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. S.","family":"Hagedorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Trefz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"van Vliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. J.","family":"van Spronsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"issue":"9750","key":"1647_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376(9750):1417\u201327.","journal-title":"Lancet"},{"key":"1647_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/1750-1172-8-191","volume":"8","author":"TS Hagedorn","year":"2013","unstructured":"Hagedorn TS, et al. Requirements for a minimum standard of care for phenylketonuria: the patients\u2019 perspective. Orphanet J Rare Dis. 2013;8:191.","journal-title":"Orphanet J Rare Dis"},{"key":"1647_CR3","unstructured":"EUCERD, Recommendations on quality criteria for centres of expertise for rare diseases in member states 2011. www.eucerd.eu."},{"issue":"Suppl 3","key":"1647_CR4","first-page":"s621","volume":"12","author":"D Taruscio","year":"2014","unstructured":"Taruscio D, et al. Centres of Expertise and European Reference Networks: key issues in the field of rare diseases. EUCERD Recomm Blood Transfus. 2014;12(Suppl 3):s621\u20135.","journal-title":"EUCERD Recomm Blood Transfus"},{"issue":"2\u20133","key":"1647_CR5","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.healthpol.2012.02.008","volume":"105","author":"H Hannemann-Weber","year":"2012","unstructured":"Hannemann-Weber H, Kessel M, Schultz C. Research performance of centers of expertise for rare diseases\u2014the influence of network integration, internal resource access and operational experience. Health Policy. 2012;105(2\u20133):138\u201345.","journal-title":"Health Policy"},{"issue":"1","key":"1647_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/s13023-019-1130-5","volume":"14","author":"U Plockinger","year":"2019","unstructured":"Plockinger U, Ziagaki A. The German National Action League for people with rare diseases: translating the three tiers center system into active co-operation, a one center experience. Orphanet J Rare Dis. 2019;14(1):158.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1647_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jpeds.2004.04.029","volume":"145","author":"CS Camfield","year":"2004","unstructured":"Camfield CS, et al. Optimal management of phenylketonuria: a centralized expert team is more successful than a decentralized model of care. J Pediatr. 2004;145(1):53\u20137.","journal-title":"J Pediatr"},{"issue":"1","key":"1647_CR8","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s10897-013-9642-y","volume":"23","author":"SJ DeWard","year":"2014","unstructured":"DeWard SJ, et al. Practical aspects of recruitment and retention in clinical trials of rare genetic diseases: the phenylketonuria (PKU) experience. J Genet Couns. 2014;23(1):20\u20138.","journal-title":"J Genet Couns"},{"issue":"686","key":"1647_CR9","doi-asserted-by":"publisher","first-page":"e586","DOI":"10.3399\/bjgp19X704141","volume":"69","author":"E Donaghy","year":"2019","unstructured":"Donaghy E, et al. Acceptability, benefits, and challenges of video consulting: a qualitative study in primary care. Br J Gen Pract. 2019;69(686):e586\u201394.","journal-title":"Br J Gen Pract"},{"issue":"4","key":"1647_CR10","doi-asserted-by":"publisher","first-page":"e0215203","DOI":"10.1371\/journal.pone.0215203","volume":"14","author":"K Honarmand","year":"2019","unstructured":"Honarmand K, et al. Feasibility of a web-based neurocognitive battery for assessing cognitive function in critical illness survivors. PLoS ONE. 2019;14(4):e0215203.","journal-title":"PLoS ONE"},{"issue":"4","key":"1647_CR11","doi-asserted-by":"publisher","first-page":"940","DOI":"10.3758\/BF03192989","volume":"39","author":"SM Silverstein","year":"2007","unstructured":"Silverstein SM, et al. Development and validation of a World-Wide-Web-based neurocognitive assessment battery: WebNeuro. Behav Res Methods. 2007;39(4):940\u20139.","journal-title":"Behav Res Methods"},{"key":"1647_CR12","doi-asserted-by":"crossref","unstructured":"Backx, R., et al. Bringing Home Cognitive Assessment: Initial Validation of Unsupervised Web-based Cognitive Testing on the Cambridge Neuropsychological Test Automated Battery (CANTAB) using a within-subjects counterbalanced design. Journal of Medical Internet Research 2020.","DOI":"10.2196\/preprints.16792"},{"issue":"9","key":"1647_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S2213-8587(16)30320-5","volume":"5","author":"FJ van Spronsen","year":"2017","unstructured":"van Spronsen FJ, et al. Key European guidelines for the diagnosis and management of patients with phenylketonuria. Lancet Diabetes Endocrinol. 2017;5(9):743\u201356.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1647_CR14","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","volume":"12","author":"AMJ van Wegberg","year":"2017","unstructured":"van Wegberg AMJ, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162.","journal-title":"Orphanet J Rare Dis"},{"key":"1647_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgmr.2018.10.002","volume":"17","author":"S Ford","year":"2018","unstructured":"Ford S, O\u2019Driscoll M, MacDonald A. Living with Phenylketonuria: Lessons from the PKU community. Mol Genet Metab Rep. 2018;17:57\u201363.","journal-title":"Mol Genet Metab Rep"},{"issue":"5","key":"1647_CR16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s10519-017-9863-1","volume":"47","author":"R Jahja","year":"2017","unstructured":"Jahja R, et al. Long-term follow-up of cognition and mental health in adult phenylketonuria: a PKU-COBESO study. Behav Genet. 2017;47(5):486\u201397.","journal-title":"Behav Genet"},{"issue":"4","key":"1647_CR17","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jpeds.2013.12.015","volume":"164","author":"R Jahja","year":"2014","unstructured":"Jahja R, et al. Neurocognitive evidence for revision of treatment targets and guidelines for phenylketonuria. J Pediatr. 2014;164(4):895\u20139 e2.","journal-title":"J Pediatr"},{"issue":"2","key":"1647_CR18","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/jcbfm.2014.183","volume":"35","author":"MJ de Groot","year":"2015","unstructured":"de Groot MJ, et al. Phenylketonuria: brain phenylalanine concentrations relate inversely to cerebral protein synthesis. J Cereb Blood Flow Metab. 2015;35(2):200\u20135.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"1647_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10545-017-0109-4","volume":"41","author":"J Vaclavik","year":"2018","unstructured":"Vaclavik J, et al. Structural elucidation of novel biomarkers of known metabolic disorders based on multistage fragmentation mass spectra. J Inherit Metab Dis. 2018;41(3):407\u201314.","journal-title":"J Inherit Metab Dis"},{"issue":"12","key":"1647_CR20","doi-asserted-by":"publisher","first-page":"e0143833","DOI":"10.1371\/journal.pone.0143833","volume":"10","author":"D van Vliet","year":"2015","unstructured":"van Vliet D, et al. Large neutral amino acid supplementation exerts its effect through three synergistic mechanisms: proof of principle in phenylketonuria mice. PLoS ONE. 2015;10(12):e0143833.","journal-title":"PLoS ONE"},{"issue":"3","key":"1647_CR21","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ymgme.2005.06.010","volume":"87","author":"MP Wasserstein","year":"2006","unstructured":"Wasserstein MP, et al. Cerebral glucose metabolism in adults with early treated classic phenylketonuria. Mol Genet Metab. 2006;87(3):272\u20137.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"1647_CR22","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.jpeds.2014.03.061","volume":"165","author":"S Yano","year":"2014","unstructured":"Yano S, Moseley K, Azen C. Melatonin and dopamine as biomarkers to optimize treatment in phenylketonuria: effects of tryptophan and tyrosine supplementation. J Pediatr. 2014;165(1):184\u20139 e1.","journal-title":"J Pediatr"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01647-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-020-01647-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01647-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T09:29:58Z","timestamp":1610098198000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01647-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1647"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01647-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"14 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The questionnaire did not collect personal data. Ethical consent was not sought as it was clarified at the beginning of the questionnaire that the primary purpose of the survey was to gain opinion about the role and benefit of CE centres to support patients with PKU. It was also stated that the data would be saved in an anonymized form. Adults with PKU and caregivers gave their consent by their voluntary completion and submission of the online questionnaire.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.M.J. van Wegberg has received a research grant from Nutricia, honoraria from Biomarin as speaker, and travel support from Nutricia and Vitaflo. A. MacDonald has been a member of the European Nutritionist Expert Panel Biomarin, Sapropterin Advisory Board Biomarin, the advisory board ELEMENT Danone-Nutricia, the advisory board for Arla and Applied Pharma Research, and received research funding and honoraria from Nutricia, Vitaflo International and Merck Serono. F. Trefz has received grants from Vitaflo Germany and honoraria as a speaker from Merck-Serono S.A. F.J. van Spronsen has been a member of scientific advisory boards for defects in amino acid metabolism of APR, Arla Food International, BioMarin, Eurocept Int, Lucana, Moderna TX, Nutricia, Rivium and SoBi, has received research grants from Alexion, Biomarin, Codexis, Nutricia, SoBi, and Vitaflo, has received grants from patient organizations ESPKU, Metakids, NPKUA, Stofwisselkracht, Stichting PKU research and Tyrosinemia Foundation, and has received honoraria as consultant and speaker from APR, Biomarin, MendeliKABS, SoBi, and Nutricia. D. Abeln, T. Hagedorn and E. Lange declare that they have no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}